Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival

Table 1

Demographic and treatment data on 34 patients with PMCA from appendix cancer who received neoadjuvant systemic chemotherapy prior to cytoreductive surgery and HIPEC. None of these clinical parameters were predictive of histological response.

	Patients treated with neoadjuvant chemotherapy	Patients not treated with neoadjuvant chemotherapy	𝑃 value
Age (mean)	47.9	48.8	0.66
Gender		0.53
Male	17	10
Female	17	14
Histological subtype		0.37
Signet ring	9	4
PMCA/adenocarcinoid	25	20
Lymph node status		0.62
Positive	12	7
Negative	22	17
Number of preoperative chemotherapy cycles	N/A
6 cycles	12
12 cycles	22
Chemotherapy regimens	N/A
FOLFOX	30
XELOX	4
Use of bevacizumab	N/A
Yes	21
No	13
Gross assessment of response at cytoreduction	N/A
Stable or response	16
Progression	17
Histological assessment of response
No response	24
Complete or near-complete response	10